Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases
F Rieder, C Fiocchi, G Rogler - Gastroenterology, 2017 - Elsevier
In the last 10 years, we have learned much about the pathogenesis, diagnosis, and
management of intestinal fibrosis in patients with inflammatory bowel diseases. Just a …
management of intestinal fibrosis in patients with inflammatory bowel diseases. Just a …
The charming world of the extracellular matrix: a dynamic and protective network of the intestinal wall
The intestinal extracellular matrix (ECM) represents a complex network of proteins that not
only forms a support structure for resident cells but also interacts closely with them by …
only forms a support structure for resident cells but also interacts closely with them by …
European evidence-based consensus: inflammatory bowel disease and malignancies
V Annese, L Beaugerie, L Egan… - Journal of Crohn's …, 2015 - academic.oup.com
The global prevalence of cancer is increasing, largely as more patients are living into old
age. Therefore, gastroenterologists caring for patients with inflammatory bowel disease [IBD] …
age. Therefore, gastroenterologists caring for patients with inflammatory bowel disease [IBD] …
hucMSC-derived exosomes attenuate colitis by regulating macrophage pyroptosis via the miR-378a-5p/NLRP3 axis
X Cai, Z Zhang, J Yuan, DKW Ocansey, Q Tu… - Stem cell research & …, 2021 - Springer
Background Human umbilical cord mesenchymal stem cell (hucMSC)-derived exosomes
are recognized as novel cell-free therapeutic agents for inflammatory bowel disease (IBD), a …
are recognized as novel cell-free therapeutic agents for inflammatory bowel disease (IBD), a …
Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation
Background & Aims Intestinal fibrosis is a long-term complication in inflammatory bowel
diseases (IBD) that frequently results in functional damage, bowel obstruction, and surgery …
diseases (IBD) that frequently results in functional damage, bowel obstruction, and surgery …
Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics
Q Lu, M Yang, Y Liang, J Xu, H Xu, Y Nie… - Journal of …, 2022 - Taylor & Francis
As a main digestive organ and an important immune organ, the intestine plays a vital role in
resisting the invasion of potential pathogens into the body. Intestinal immune dysfunction …
resisting the invasion of potential pathogens into the body. Intestinal immune dysfunction …
The Nrf2 in the pathophysiology of the intestine: Molecular mechanisms and therapeutic implications for inflammatory bowel diseases
M Piotrowska, M Swierczynski, J Fichna… - Pharmacological …, 2021 - Elsevier
Abstract Nrf2 (nuclear factor erythroid 2-related factor 2) is a stress-responsive transcription
factor, associated with cellular homeostasis. Under normal conditions Nrf2 is kept in the …
factor, associated with cellular homeostasis. Under normal conditions Nrf2 is kept in the …
European Crohn's and Colitis Organisation topical review on prediction, diagnosis and management of fibrostenosing Crohn's disease
F Rieder, G Latella, F Magro, ES Yuksel… - Journal of Crohn's …, 2016 - academic.oup.com
This ECCO topical review of the European Crohn's and Colitis Organisation [ECCO] focused
on prediction, diagnosis, and management of fibrostenosing Crohn's disease [CD]. The …
on prediction, diagnosis, and management of fibrostenosing Crohn's disease [CD]. The …
Matrix metalloproteinases in inflammatory bowel disease: an update
Matrix metalloproteinases (MMPs) are known to be upregulated in inflammatory bowel
disease (IBD) and other inflammatory conditions, but while their involvement is clear, their …
disease (IBD) and other inflammatory conditions, but while their involvement is clear, their …
Mechanisms of initiation and progression of intestinal fibrosis in IBD
G Latella, J Di Gregorio, V Flati, F Rieder… - Scandinavian journal …, 2015 - Taylor & Francis
Intestinal fibrosis is a common complication of the inflammatory bowel diseases (IBDs). It
becomes clinically apparent in> 30% of patients with Crohn's disease (CD) and in about 5 …
becomes clinically apparent in> 30% of patients with Crohn's disease (CD) and in about 5 …